HeartSciences is a pre-revenue medical technology company developing AI-powered ECG algorithms ("AI-ECG") designed to detect structural and ischemic heart disease — conditions that conventional ECGs are poor at identifying. HeartSciences has two planned products. The first is the MyoVista wavECG, a proprietary 12-lead resting ECG hardware device bundled with a HeartSciences AI algorithm for detecting impaired left ventricular relaxation, targeting frontline clinical settings like primary care and urgent care. The second is the MyoVista Insights Cloud Platform, a device-agnostic, cloud-based platform that accepts ECG data from any existing ECG device and runs AI-ECG algorithms on that data — both HeartSciences' own and third-party algorithms. Neither product has received FDA clearance yet. HeartSciences plans to generate recurring revenue through a razor-razorblade model on the hardware device (single-use electrode cables plus per-test software fees) and a subscription or per-use model on the cloud platform. A key revenue driver is insurance reimbursement: the AMA has issued a temporary CPT Category III code for AI-assisted ECG analysis, though permanent Category I codes are not yet secured. HeartSciences has licensed a portfolio of AI-ECG algorithms from Mount Sinai, covering multiple cardiovascular conditions, and in June 2025 received FDA Breakthrough Device designation for its aortic stenosis algorithm. The company employs 15 people and will need additional capital to fund a commercial launch after FDA clearance.